Joel Kaye

Joel Kaye has extensive work experience in the pharmaceutical industry. Joel is currently the Senior Vice President of Nonclinical Development at 1E Therapeutics since March 2022. Prior to this, Joel worked at Teva Pharmaceuticals in various roles, including Director of Pharmacology Project Leader and Associate Director of Pharmacology Project Leader. Joel was also the Head of Cancer Pharmacology and New Model Development. From 2018 to 2022, Joel served as the VP of Research and Non-Clinical Development at Ayala Pharmaceuticals. Joel also held positions at Teva Pharmaceuticals Ltd, where they were a Team Leader in the Pharmacology Department and a Senior Manager. Joel began their career as a Group Leader at Medgenics and as a Postdoctoral Fellow at Harvard Medical School. Joel obtained their PhD in 2000 while working as a PhD Student at the Weizmann Institute of Science.

Joel Kaye has a diverse educational background in the field of immunology. Joel first pursued their Bachelor of Science (BSc, Hons) degree in Pathology at The University of Western Australia from 1990 to 1994. Following this, they went on to complete a Ph.D. in Immunology at the Weizmann Institute of Science, graduating in the year 2000. After their Ph.D., Joel pursued further specialization by attending Harvard Medical School where they completed a PostDoc in Immunology from 2001 to 2003. Prior to these academic pursuits, Joel attended Carmel School from 1984 to 1988, although no specific degree or field of study is provided for this period.